AN2 Therapeutics, Inc., (ANTX) News
Filter ANTX News Items
ANTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ANTX News From Around the Web
Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.
Immuneering Leads The Pack Of 3 US Penny Stocks To MonitorAs the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and S&P 500 showing gains, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond well-known names. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when... |
AN2 Therapeutics to Participate at Upcoming Investor ConferencesMENLO PARK, Calif., November 14, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. |
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry PipelineMENLO PARK, Calif., November 13, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial. |
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and MalariaMENLO PARK, Calif., October 17, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria. |
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceMENLO PARK, Calif., August 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. |
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's WhyAN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results. |
AN2 Therapeutics Adopts Limited Duration Stockholder Rights PlanMENLO PARK, Calif., August 16, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. |
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific HighlightsMENLO PARK, Calif., August 13, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30, 2024. |
Top Midday DeclinersTop Midday Decliners |
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves WorkforceOn Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in treatment-refractory mycobacterium avium complex (MAC) lung disease. The Phase 2 part of the study met its primary objective of demonstrating the potential validation of a novel patient-reported outcome (PRO) tool and a higher PRO-based clinical response rate in the epetraborole + OBR arm (39.5%) vs. pla |